National Cancer Institute Awards SBIR Contract to Rules-Based Medicine
News Dec 23, 2008
Rules-Based Medicine, Inc. (RBM) and Correlogic Systems, Inc. have announced the award of a National Cancer Institute (NCI) Small Business Innovation Research (SBIR) contract to RBM that will further research on ovarian cancer diagnostic tests.
The contract was awarded through a peer-reviewed competitive process to develop biomarker panels for the early detection of cancer and includes a Phase I Fast-Track component and Phase II option, together totaling $1.15 million.
"An early diagnostic screen for ovarian cancer could greatly increase the chances of survival," said Craig Benson, RBM's chief executive officer. "Our research will integrate additional biomarkers associated with ovarian cancer into the existing Correlogic panel with the aim of achieving sensitivity and specificity levels that can open this test to a wider population of women."
"Our search for additional biomarkers - and combinations of biomarkers - for early disease detection is an ongoing effort," said Peter Levine, Correlogic's president and chief executive officer. "We are building on Correlogic's extensive research and validation using multiple markers for disease detection to take our test to the next level."
Under the two phases of this project, RBM will develop and test quantitative, multiplexed immunoassays incorporating 19 additional analytes the two companies have identified as promising targets potentially capable of enhancing accuracy of ovarian cancer detection.
Correlogic will expand its existing analytic platform to determine the efficacy of incorporating these additional analytes into the existing assay. Upon completion RBM will add the 19 assays to its automated RBM Human Multi-Analyte Profile platform, HumanMAP®.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE